Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2009

View Archived Issues

Preclinical and phase I data on PI3 and mTOR kinase inhibitor GDC-0980 presented

Lentiviral vector gene therapy for X-linked adrenoleukodystrophy / News in Context

Selumetinib exhibits modest activity in AML in phase II trial

CORE trial data suggest efficacy of deferasirox in hereditary hemochromatosis

AJM-300 shows clinical activity in patients with active Crohn's disease

Preclinical and early phase I data suggest activity of JI-101 in solid tumors

Panacea Biotec claims novel compounds for the treatment of bacterial infections

Novel S1P1/edg1 receptor agonists in early development at Actelion

Takeda discloses novel ACC inhibitors for the treatment of obesity

Intellikine describes novel PI3K and mTOR inhibitors for the treatment of cancer

Novel GK activators claimed by Roche as antidiabetic agents

Alkermes licenses Medifusion technology platform from Acceleron

BioAlliance Pharma reports phase II survival data on doxorubicin Transdrug

Curis reports preclinical data on HSP 90 inhibitor CUDC-305

Stockholders approve Anesiva merger with Arcion Therapeutics

FDA approves initiation of clinical studies of Taro's T-2000 in the U.S.

Neoprobe's Lymphoseek achieves primary endpoint in phase III trial

Allos Therapeutics forms agreement with Idis for Folotyn

Janssen-Cilag submits MAA in Europe for paliperidone palmitate for schizophrenia

Oxygen Biotherapeutics enrolls first patient in Oxycyte trial in traumatic brain injury

Pharmaxis reports sustained benefit with Bronchitol in phase III trial in cystic fibrosis

Phase I/II clinical data reported for BiondVax's universal flu vaccine

Pluristem Therapeutics doses first patients in Europe with placenta-derived cell therapy

Provectus reports phase II data for PH-10 in psoriasis and atopic dermatitis

Roche to discontinue development of RG-1507

Radient receives Korean approval for its in vitro diagnostic cancer test Onko-Sure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...